Current Canadian GLP-1 Medications Health Canada has approved several GLP-1 medications that are currently available across Canadian provinces: Ozempic (semaglutide): Injectable medication manufactured by Novo Nordisk Wegovy (semaglutide): Higher-dose injectable formulation from Novo Nordisk Mounjaro (tirzepatide): Weekly injection produced by Eli Lilly Rybelsus (semaglutide): Daily oral tablet approved by Health Canada in April 2020 Impact on Generic Applications The WHO recommendation comes as Health Canada reviews nine generic semaglutide applications following patent expiry on January 4, 2026
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Heres the unfiltered truth: Kaiser Permanentes coverage for weight loss medications is highly variable and often restrictive
Many patients administer both on the same day for convenience, while others space them throughout the week based on personal preference and symptom management
If treatment is stopped, the factors that previously contributed to weight gain may return
Patients on semaglutide, tirzepatide, or similar drugs should be mindful of their mood and communicate changes to their clinicians